Mainz Biomed announced a partnership with Trusted Health Advisors. “As we make the final preparations to commence patient enrollment in the ReconAAsense trial and given the potentially transformative role the test will have on the market if approved, we are excited by the opportunity to be in a position to advance our U.S. go-to-market strategy for our innovative approach in CRC screening,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Through our partnership with THA, we plan to expedite and enhance the deployment of our differentiated commercial strategy to enable an efficient and impactful transition to the marketplace for the product which if approved, we anticipate will occur in 2026. We look forward to working with Drs. Wohlgemuth, Tabibiazar and the entire THA team.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MYNZ:
- Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
- MYNZ Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Mainz Biomed to showcase ColoAlert at Gynecology Conference
- Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community
- Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®